Atezolizumab is an anti-PD-L1 directed drug and has been approved as first- and second-line therapy for lung cancer regardless of PD-L1 status (determined by VENTANA PD-L1 (SP 142 assay). The gene discussed is CD274; the disease is lung cancer.